Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - Company News (73 News)
Country: Germany · Primary market: Germany · EQS NID: 1936937
01 July 2024 11:31AM

CGM receives C5 attestation according to BSI Criteria


EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous
CGM receives C5 attestation according to BSI Criteria

01.07.2024 / 11:31 CET/CEST
The issuer is solely responsible for the content of this announcement.


CGM receives C5 attestation according to BSI Criteria  

Koblenz - CompuGroup Medical (CGM) has received C5 attestation (Type 1) for cloud services in Germany in accordance with the criteria of the German Federal Office for Information Security (BSI). Cloud products of CGM have been attested compliance with C5 criteria retroactively as of May 31, 2024 by an independent auditing company.

The German Digital Act (DigiG) prescribes C5 (Type 1) as the security standard for cloud services in the German healthcare and social services sector from July 1, 2024. C5 (Cloud Computing Compliance Criteria Catalogue) was developed by the BSI and specifies requirements for secure cloud computing. It contains more than 120 security criteria, including the areas of information security organization, physical security, regular operations, portability and interoperability. These criteria are regularly reviewed by independent auditors.

“CompuGroup Medical offers its customers high security standards in the processing of healthcare data. The C5-attested cloud applications in Germany are another milestone on this path,” says Michael Rauch, CEO of CompuGroup Medical. 

The C5 attestation provides customers with important guidance when selecting a cloud provider and supports healthcare professionals in meeting the strict requirements for information security. Based on a standardized examination and report, it provides transparency on the information security status of a cloud service.

Further information on the C5 attestation for CGM can be found here: www.cgm.com/c5-testat

 



01.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1936937

 
End of News EQS News Service

1936937  01.07.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1936937&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.